Download Free Medical DEMYELINATING DISEASE MULTIPLE SCLEROSIS PowerPoint Presentation

DEMYELINATING DISEASE MULTIPLE SCLEROSIS PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Neurology, which is titled "DEMYELINATING DISEASE MULTIPLE SCLEROSIS", to know about multiple sclerosis.

Tags : Neurology, DEMYELINATING DISEASE, multiple sclerosis

Published on : Aug 23, 2021 | Views : 2021 | Downloads : 12

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

DEMYELINATING DISEASE MULTIPLE SCLEROSIS ELLEN MARDER MD PHD, 8/4/2005
Slide 2-

MYELIN PROTEOLIPID INSULATION OF AXONS ENHANCES NERVE SIGNAL TRANSMISSION SUPPORTS AXON FUNCTION OLIGODENDROCYTES FORM CNS MYELIN SCHWANN CELLS FORM PNS MYELIN
Slide 3-

DEMYELINATION DESTRUCTION OF MYELIN ETIOLOGIES Infection: Progressive multifocal leuko- encephalopathy (PML) Postinfectious:Guillain Barre Syndrome (AIDP) Autoimmune: Multiple sclerosis Genetic/metabolic: Adrenoleukodystrophy
Slide 4-

DEMYELINATING DISEASES CENTRAL NERVOUS SYSTEM: Multiple sclerosis, progressive multifocal leukoencephalopathy, acute disemminated encephalomyelitis, adrenoleukodystrophy PERIPHERAL NERVOUS SYSTEM: Guillain Barre Syndrome(AIDP), chronic inflammatory demyelinating polyneuropathy(CIDP)
Slide 5-

ACUTE V CHRONIC ACUTE or SUBACUTE: ADEM, GBS, PML CHRONIC: MS, CIDP, ALD, MLD
Slide 6-

RESULTS OF DEMYELINATION CONDUCTION BLOCK AXONAL DEATH
Slide 7-

MULTIPLE SCLEROSIS Chronic central nervous system demyelinating disease 85% relapsing - remitting Most common cause of nontraumatic disability in young adults Prevalence in the US – 400, 000 Reduction in life expectancy <5-7 years
Slide 8-

INTERNAL MEDICINE AND MULTIPLE SCLEROSIS (MS) INVOLVEMENT AT EVERY STAGE Recognition: first clinical episode Referral: for diagnosis and treatment Return or continuing care: for health maintainence and treatment of the complications of chronic disease
Slide 9-

WHAT IS MS? MS is an autoimmune disease caused by myelin-reactive T cells in the peripheral circulation that become activated by a trigger (?viral or bacterial), invade the central nervous system and cause destruction of myelin and axons directly and by initiating the release of various inflammatory mediators. There is often ineffective or no repair of damage.
Slide 10-

IMMUNOLOGY-MS
Slide 11-

PATHOPHYSIOLOGY OF MS Focal areas of myelin destruction associated with inflammatory infiltrates (T-cells, macrophages) around periventricular venules Axonal loss – even in early stages Eventual scarring and more axonal loss Brain atrophy
Slide 12-

MULTIPLE SCLEROSIS GROSS PATHOLOGY
Slide 13-

MRI in MS
Slide 14-

EARLY AXONAL INJURY
Slide 15-

BRAIN ATROPHY
Slide 16-

DIAGNOSIS - TRADITIONAL The demonstration of abnormal physical SIGNS indicating the presence of lesions at TWO SEPARATE sites in the CNS, in an individual with a history of at least two episodes of neurological disturbance of the kind seen in MS, and there is no better explanation for the clinical picture. THESE CRITERIA CAN BE FULFILLED BY CLINICAL ASSESSMENT ALONE
Slide 17-

LABORATORY ASSISTED DIAGNOSIS MS lesions in various stages can now be seen on MRI Cerebrospinal fluid analysis can identify immunoglobulin synthesis Evoked potentials can demonstrate clinically and even MRI silent lesions
Slide 18-

NEW DIAGNOSTIC CRITERIA (MacDonald Criteria*) Allows separation in space criterion to be met by MRI lesions or evoked potential abnormalities (e.g. visual evoked response or VER) Allows new MRI lesions or contrast enhancing lesions to substitute for a second physical sign or clinical attack McDonald Ann Neurol 2001;50:121
Slide 19-

DIAGNOSIS – HOW EARLY? CHAMPS STUDY* First isolated, well defined neurologic event: optic nerve,spinal cord,brain stem or cerebellum, clinically documented At least 2 (>3mm) MRI lesions characteristic of MS 50% chance of another attack in 3 years 35% chance of second attack if treated with weekly interferon beta-1a Jacobs NEJM 2000; 343:898
Slide 20-

MRI - DISEASE SURROGATE? Easily accomplished Objective Readily measurable – volume and number of lesions, enhancement of lesions, brain atrophy Weak correlation with disability
Slide 21-

IS IT MS? Women 2x> men Peak incidence 3rd and 4th decade Highest incidence in Caucasians Increased incidence with distance from equator Family history: 50% concordance in identical twins and 5% increased incidence among first degree relatives
Slide 22-

MS: PRESENTATION Visual: loss, dim, blurred (49%) Oculomotor: impaired eye movements, nystagmus(42%) Paresis:unilateral,mono-,paraparesis(42%) Incoordination:extremity,gait,tremor(23%) GU/bowel: incontinence, retention(10%) Cerebral: cognitive impairment(4%)
Slide 23-

CLINICAL COURSE RELAPSES 58% Have one relapse in first 2 years 21% Have two relapses “ 9% Have 3 or more attacks 80% Have full recovery There is a correlation between relapses in the first two years and the time to significant disability* Weinshenker Brain 1989;112:1419
Slide 24-

CLINICAL COURSE 10-15% “Benign” disease – patients fully functional at 15 years after disease onset Less than 10% have “malignant” disease – rapid progression to significant disability or death in a short time Over 50% accumulate neurologic deficits over time, that affect gait, coordination, vision, and cognitive function. Once accumulation starts, time to significant disability is predictable – 4-6 years* Confavreaux NEJM 2000;343:1430
Slide 25-

CLINICAL COURSE CHRONIC DEFICITS* 100% Develop problems with vision 88% Develop problems with weakness – usually paraparesis 82% Develop some form of incoordination 63% Have problems with bladder and/or bowels 39% (conservative estimate) have cognitive impairment Whitaker Multiple Sclerosis 1997: 3-19
Slide 26-

TREATMENT EXACERBATIONS RELAPSING AND REMITTING DISEASE REFRACTORY RELAPSING REMITTING DISEASE CHRONIC PROGRESSIVE DISEASE
Slide 27-

TREATMENT OF EXACERBATIONS Methylprednisolone 500-1000mg qd x 5 +/- oral taper (Durelli Neurology 1986;36: 238) Oral high dose steroids(Morrow Neurology2004;63:1079) Plasma exchange(WeinshenkerAnn Neurol 1999;46:878) Intravenous immunoglobulin (AchironNeurology 1998;50:398)
Slide 28-

DISEASE MODULATING AGENTS All demonstrate reduction of clinical relapses (30%) and new MRI lesions in 3 year double blind, placebo-controlled studies. They are FDA approved INTERFERONS Beta interferon-1a: Avonex, Rebif Beta interferon-1b: Betaseron GLATIRAMER ACETATE: Copaxone Galetta.Archives of Int Med. 2002;162:2161
Slide 29-

INTERFERONS Part of the innate immune system Up-regulates immunosuppression Blocks entry of activated T-cells into the CNS
Slide 30-

INTERFERONS Injected IM weekly, SC tiw or qod Injections side reactions Common side effects: flu-like syndrome with headache, fever, myalgias Hepatic enzyme elevations, bone marrow suppresion Antibody formation affects efficacy
Slide 31-

GLATIRAMER ACETATE (COPAXONE) Random copolymer of amino acids alanine, lysine, glutamic acid, tyrosine Interferes with antigen presentation and T-cell activation Drives T-cell population to Th2 type - suppression
Slide 32-

GLATIRAMER ACETATE Daily subcutaneous injection Injection site reactions: erythema, lipodystrophy Idiosyncratic reactions: chest tightness, shortness of breath, usually single episode
Slide 33-

REFRACTORY R-R MS ADD-ON THERAPY High dose methylprednisolone pulse therapy IVIG Plasma exchange Immunosuppressives -mitoxantrone -cyclophosphamide -azathioprine -methotrexate
Slide 34-

MITOXANTRONE (NOVANTRONE*) FDA approved Inhibits DNA synthesis Infusions well tolerated Side effects: cardiomyopathy, leukemia Infusions every 3 months 12mg/m2; total 82 mg Millefiorini J Neuro 1997;244:153l
Slide 35-

CONCLUSION MS is a chronic immunologic disease caused by peripheral T-cell activation in a susceptible host The clinical course is variable but it results in significant disability for the majority MS patients should be treated at the time of diagnosis because those at risk cannot be identified
Slide 36-

CONCLUSION MRI is now used as a surrogate for disease activity for treatment and drug testing There is no long term data on the value of MRI as a surrogate marker Suppression of clinical and MRI evidence of disease activity are now treatment goals
Slide 37-

CONCLUSION There is no evidence that suppression of disease activity clinically or on MRI affects long-term outcome but despite that there is a general feeling that early treatment will be beneficial in the long run.